<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993014</url>
  </required_header>
  <id_info>
    <org_study_id>2861/20</org_study_id>
    <nct_id>NCT04993014</nct_id>
  </id_info>
  <brief_title>Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer</brief_title>
  <acronym>HER2Cell</acronym>
  <official_title>Circulating Tumor Cells and Adjuvant Treatment De-escalation After Neoadjuvant Therapy With Trastuzumab and Pertuzumab for HER2 Positive Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AC Camargo Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AC Camargo Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II unicentric randomized trial which will include early HER2 positive breast cancer&#xD;
      patients, candidate to neoadjuvant therapy with trastuzumab and pertuzumab. Circulating tumor&#xD;
      cells will be collected at neoadjuvant therapy baseline.&#xD;
&#xD;
      Patients with pathological complete response will be randomized in 1:1 ratio for adjuvant&#xD;
      trastuzumab (arm A) versus trastuzumab + pertuzumab (arm B) in a two factorial design: group&#xD;
      A, with HER2 positive CTCs and group B, with HER2 negative/absent CTCs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with HER2 positive breast cancer (hormone receptors positive or negative), which are&#xD;
      candidate to neoadjuvant therapy with pertuzumab and trastuzumab will be included.&#xD;
&#xD;
      Blood samples will be collected at baseline (before neoadjuvant start) for the analysis of&#xD;
      CTCs and its positivity for HER2 by IHC and ISH.&#xD;
&#xD;
      Patients with pathological complete response will be included in the randomization phase of&#xD;
      the study. There will be 2 cohorts: HER2 positive CTCs at baseline and HER2 negative/absent&#xD;
      CTCs at baseline. In each cohort, patients will be randomized in 1:1 ratio for adjuvant&#xD;
      trastuzumab versus adjuvant trastuzumab + pertuzumab&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Patients will be divided into 2 cohorts, based on HER2 positivity in CTCs at baseline of neoadjuvant therapy.&#xD;
Cohort 1: HER2 positive CTCs: randomization to adjuvant trastuzumab versus trastuzumab + pertuzumab in patients with pathological complete response Cohort 2: HER2 negative/absent CTCs: randomization to adjuvant trastuzumab versus trastuzumab + pertuzumab in patients with pathological complete response</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HER2 therapy disease-free survival</measure>
    <time_frame>From adjuvant therapy initiation to recurrence or death by any cause, whichever came first, assessed up to 5 years</time_frame>
    <description>To compare the disease-free survival between trastuzumab and trastuzumab + pertuzumab arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTCs disease-free survival</measure>
    <time_frame>From adjuvant therapy initiation to recurrence or death by any cause, whichever came first, assessed up to 5 years</time_frame>
    <description>To compare the disease-free survival between patients with HER2 positive CTCs at baseline versus HER2 negative/absent CTCs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic factors for disease-free survival</measure>
    <time_frame>At baseline and adjuvant therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of CTCs and pathological complete response</measure>
    <time_frame>At baseline</time_frame>
    <description>To evaluate if there is a correlation of HER2 positivity and the number of CTCs/ml and the pathological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Adjuvant period (1 year)</time_frame>
    <description>To compare the adverse events between trastuzumab and trastuzumab + pertuzumab</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Arm A - trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant trastuzumab for patients with HER2 positive CTCs at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant trastuzumab + pertuzumab for patients with HER2 positive CTCs at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Arm A - trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant trastuzumab for patients with HER2 negative/absent CTCs at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant trastuzumab + pertuzumab for patients with HER2 negative/absent CTCs at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)</description>
    <arm_group_label>Cohort 1, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <arm_group_label>Cohort 2, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts</description>
    <arm_group_label>Cohort 1, Arm A - trastuzumab</arm_group_label>
    <arm_group_label>Cohort 1, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <arm_group_label>Cohort 2, Arm A - trastuzumab</arm_group_label>
    <arm_group_label>Cohort 2, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <other_name>Zedora</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Circulating tumor cells</intervention_name>
    <description>Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.</description>
    <arm_group_label>Cohort 1, Arm A - trastuzumab</arm_group_label>
    <arm_group_label>Cohort 1, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <arm_group_label>Cohort 2, Arm A - trastuzumab</arm_group_label>
    <arm_group_label>Cohort 2, Arm B - Trastuzumab + pertuzumab</arm_group_label>
    <other_name>CTCs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HER2 positive breast cancer (hormone receptors positive or negative)&#xD;
&#xD;
          -  Stage I to III&#xD;
&#xD;
          -  Indication for neoadjuvant therapy with chemo (any regimen) + trastuzumab + pertuzumab&#xD;
&#xD;
          -  Breast surgery after neoadjuvant therapy&#xD;
&#xD;
          -  Preserved coagnition&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
          -  For the randomization phase: pathological complete response (ypT0/ypTis and ypN0)&#xD;
&#xD;
          -  Agreement on participation and signature of de ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contradindication for trastuzumab or pertuzumab&#xD;
&#xD;
          -  Adjuvant chemotherapy. Hormone therapy is allowed&#xD;
&#xD;
          -  Second primary tumor &lt; 5 years, with an exception for treated non-melanoma skin&#xD;
             cancer, and in situ cervical cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelle G Cesca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.C. Camargo Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelle G Cesca, MD</last_name>
    <phone>+551121895000</phone>
    <email>marcelle.cesca@accamargo.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludmilla TD Chinen, PhD</last_name>
    <phone>+551121895000</phone>
    <email>ludmilla.chinen@accamargo.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.C. Camargo Cancer Center</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>01525-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelle G Cesca, MD</last_name>
      <phone>+551121895000</phone>
      <email>marcelle.cesca@accamargo.org.br</email>
    </contact>
    <contact_backup>
      <last_name>Ludmilla TD Chinen, PhD</last_name>
      <phone>+551121895000</phone>
      <email>ludmilla.chinen@accamargo.org.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AC Camargo Cancer Center</investigator_affiliation>
    <investigator_full_name>Marcelle Goldner Cesca</investigator_full_name>
    <investigator_title>Clinical Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

